Ta strona używa pliki cookies, w celu polepszenia użyteczności i funkcjonalności oraz w celach statystycznych. Dowiedz się więcej w Polityce prywatności.
Korzystając ze strony wyrażasz zgodę na używanie plików cookies, zgodnie z aktualnymi ustawieniami przeglądarki.
Akceptuję wykorzystanie plików cookies
eISSN: 2449-8238
ISSN: 2392-1099
Clinical and Experimental Hepatology
Current issue Archive Manuscripts accepted About the journal Editorial board Subscription Contact Instructions for authors Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
4/2024
vol. 10
 
Share:
Share:
Original paper

Prevalence and risk factors of liver fibrosis in patients with metabolic-associated fatty liver disease undergoing bariatric surgery

Amr Elsayed
1
,
Alshymaa Hassnine
1
,
Mariana F. Gayyed
2
,
Fatma Saied
1
,
Mohamed A. Abdelzaher
3
,
Yasser Fouad
1
,
Alaa M. Mostafa
1
,
Mohamed Khalaf
3

  1. Department of Gastroenterology, Hepatology and Endemic Medicine, Faculty of Medicine, Minia University, Egypt
  2. Department of Pathology, Faculty of Medicine, Minia University, Egypt
  3. Department of Surgery, Faculty of Medicine, Minia University, Egypt
Clin Exp HEPATOL 2024; 10, 4: 240-248
Online publish date: 2024/12/11
Article file
- Prevalence (2).pdf  [0.11 MB]
Get citation
 
PlumX metrics:
 
1. Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 2016; 64: 73-84.
2. Eslam M, Sarin SK, Wong VWS, et al. The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease. Hepatol Int 2020; 14: 889-919.
3. Younossi Z, Anstee QM, Marietti M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol 2018; 15: 11-20.
4. Tomah S, Hamdy O, Abuelmagd MM, et al. Prevalence of and risk factors for non-alcoholic fatty liver disease (NAFLD) and fibrosis among young adults in Egypt. BMJ Open Gastro 2021; 8: e000780.
5. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American association for the study of liver diseases. Hepatology 2018; 67: 328-357.
6. European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD) and European Association for the Study of Obesity (EASO). EASL-EASD-
7. EASO EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease. J Hepatol 2016; 64: 1388-1402.
8. Angulo P, Hui JM, Marchesini G, et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 2007; 45: 846-854.
9. Sterling RK, Lissen E, Clumeck N, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 2006; 43: 1317-1325.
10. Wai CT, Greenson JK, Fontana RJ, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003; 38: 518-526.
11. Aboulghate M, Elaghoury A, Elebrashy I. The burden of obesity in Egypt. Front Public Health 2021; 9: 718978.
12. Alebshehy R, Shuaib NM, Mbako JD, et al. Determinant analysis of obesity among adult females in Egypt. Egypt J Hosp Med 2016; 65: 662-669.
13. World Health Organization. Egypt National STEPwise Survey for no communicable diseases risk factors report (2017). Accessed: October 11, 2020.
14. Yang W, Wang C. Metabolic surgery needs stronger endorsement in Asian T2DM patients with low BMI. Obes Surg 2022; 32: 212-213.
15. Wu S, Wu F, Ding Y, et al. Association of non-alcoholic fatty liver disease with major adverse cardiovascular events: a systematic review and meta-analysis. Sci Rep 2016; 6: 33386.
16. Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41: 1313-1321.
17. Bedossa P, Poitou C, Veyrie N, et al. Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients. Hepatology 2012; 56: 1751-1759.
18. Subichin M, Clanton J, Makuszewski M, et al. Liver disease in the morbidly obese: A review of 1000 consecutive patients undergoing weight loss surgery. Surg Obes Relat Dis 2015; 11:
19. 137-141.
20. Udelsman BV, Corey KE, Lindvall C, et al. Risk factors and prevalence of liver disease in review of 2557 routine liver biopsies performed during bariatric surgery. Surg Obes Relat Dis 2019; 15: 843-849.
21. Tseng J, Korman J, Noureddin M, et al. Routine versus selective liver biopsy during bariatric surgery: Postoperative outcomes and preoperative predictors of NASH. Obes Surg 2022; 32:
22. 463-471.
23. Pais R, Aron-Wisnewsky J, Bedossa P, et al. Persistence of severe liver fibrosis despite substantial weight loss with bariatric surgery. Hepatology 2022; 76: 456-468.
24. Loria P, Lonardo A, Anania F. Liver and diabetes. A vicious circle. Hepatol Res 2013; 43: 51-64.
25. Vallet-Pichard A, Mallet V, Nalpas B, et al. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest. Hepatology 2007; 46: 32-36.
26. Ciardullo S, Monti T, Perseghin G. High prevalence of advanced liver fibrosis assessed by transient elastography among U.S. adults with type 2 diabetes. Diabetes Care 2021; 44: 519-525.
27. Ampuero J, Pais R, Aller R, et al. Development and validation of hepamet fibrosis scoring system-a simple, noninvasive test to identify patients with nonalcoholic fatty liver disease with advanced fibrosis. Clin Gastroenterol Hepatol 2020; 18: 216-225.e5.
28. Labenz C, Huber Y, Kalliga E, et al. Predictors of advanced fibrosis in non-cirrhotic non- alcoholic fatty liver disease in Germany. Aliment Pharmacol Ther 2018; 48: 1109-1116.
29. Yang S, Cheng J, Zhang R, et al. Metabolic dysfunction associated fatty liver disease and liver fibrosis: Prevalence and associated factors in the middle aged and older US population. Hepatol Res 2022; 52: 176-186.
30. Younossi Z, Loomba R, Anstee QM, et al. Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis. Hepatology 2018; 68: 349-360.
31. Pappachan JM, Babu S, Krishnan B, et al. Non-alcoholic fatty liver disease: A clinical update. J Clin Transl Hepatol 2017; 5: 384-393.
32. Lin H, Zhang X, Li G, et al. Epidemiology and clinical outcomes of metabolic (dysfunction)- associated fatty liver disease. J Clin Transl Hepatol 2021; 9: 972-982.
33. Jun DW, Kim SG, Park SH, et al. External validation of the non-alcoholic fatty liver disease fibrosis score for assessing advanced fibrosis in Korean patients. J Gastroenterol Hepatol 2017; 32: 1094-1099.
34. Huang Y, Dong S, Wang C, et al. Significant fibrosis assessed by liver biopsy among Chinese bariatric surgery patients: A prospective cross-sectional study. Front Endocrinol 2023; 14: 1090598.
35. Zambrano-Huailla R, Guedes L, Stefano JT, et al. Diagnostic performance of three non- invasive fibrosis scores (Hepamet, FIB-4, NAFLD fibrosis score) in NAFLD patients from a mixed Latin American population. Ann Hepatol 2020; 19: 622-626.
36. Castera L, Friedrich-Rust M, Loomba R. Noninvasive assessment of liver disease in patients with nonalcoholic fatty liver disease. Gastroenterology 2019; 156: 1264-1281.e4.
37. Vilar-Gomez E, Chalasani N. Non-invasive assessment of non-alcoholic fatty liver disease: Clinical prediction rules and blood-based biomarkers. J Hepatol 2018; 68: 305-315.
Copyright: © Clinical and Experimental Hepatology. This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0). License (http://creativecommons.org/licenses/by-nc-sa/4.0/) enables reusers to distribute, remix, adapt, and build upon the material in any medium or format for noncommercial purposes only, and only so long as attribution is given to the creator. If you remix, adapt, or build upon the material, you must license the modified material under identical terms.
Quick links
© 2025 Termedia Sp. z o.o.
Developed by Bentus.